Treatment completion rates of olanzapine and risperidone in long acting injectable formulations for the treatment of schizophrenia: A comparison of single arm open-label studies

被引：0
|
作者：
Ascher-Svanum, H. [1 ]
Montgomery, W. [1 ]
Brnabic, A. [2 ]
Lawson, A. [1 ]
Tomori, O. [1 ]
Coleman, K. [3 ]
Lynch, L. [3 ]
Chen, P. [4 ]
Andersen, S. W. [1 ]
McDonnell, D. P. [1 ]
机构：
[1] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
[2] Eli Lilly & Co, N Ryde, NSW, Australia
[3] Hlth Technol Analysts, Balmain, NSW, Australia
[4] Eli Lilly & Co, Singapore, Singapore
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2008年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：161 / 162
页数：2
相关论文
共 50 条
  • [31] Risperidone long-acting injectable for maintenance therapy in bipolar disorder:: An open-label pilot study
    Braeunig, Peter
    Sacchett, Emilio
    Medori, Rossella
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2008, 12 (01) : 74 - 77
  • [32] Time to all-cause discontinuation following randomization to open-label olanzapine, risperidone, or conventional antipsychotic treatment for schizophrenia
    Ascher-Svanum, H
    Nyhuis, AW
    Tunis, SL
    Stevens, M
    BIOLOGICAL PSYCHIATRY, 2005, 57 (08) : 44S - 44S
  • [33] Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders
    Parellada, Eduard
    Kouniakis, Filippos
    Siurkute, Aldona
    Schreiner, Andreas
    Don, Liana
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2010, 25 (03) : 149 - 154
  • [34] COST EFFECTIVENESS OF PALIPERIDONE PALMITATE VERSUS RISPERIDONE LONG-ACTING INJECTABLE, QUETIAPINE AND OLANZAPINE FOR THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA IN COLOMBIA
    Casallas, C.
    Ariza, J. G.
    VALUE IN HEALTH, 2013, 16 (07) : A695 - A695
  • [35] Long-term treatment of chronic schizophrenia with risperidone: an open-label, multicenter study of 386 patients
    Moller, HJ
    Gagiano, CA
    Addington, DE
    Von Knorring, L
    Torres-Plank, JF
    Gaussares, C
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1998, 13 (03) : 99 - 106
  • [36] A comparative randomized, open-label, rater-blinded study of paliperidone palmitate and risperidone long-acting injectable therapy in patients with schizophrenia
    Li, H.
    Rui, Q.
    Ning, X.
    Xu, H.
    Gu, N.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 : 167 - 167
  • [37] Effectiveness of Switching From Long-Acting Injectable Fluphenazine or Haloperidol Decanoate to Long-Acting Injectable Risperidone Microspheres: An Open-Label, Randomized Controlled Trial
    Covell, Nancy H.
    McEvoy, Joseph P.
    Schooler, Nina R.
    Stroup, T. Scott
    Jackson, Carlos T.
    Rojas, Ingrid A.
    Essock, Susan M.
    JOURNAL OF CLINICAL PSYCHIATRY, 2012, 73 (05) : 669 - 675
  • [38] Treatment adherence in schizophrenia using risperidone long-acting injectable: as early as possible, as long as possible
    Viala, A.
    Boulicot, V.
    Merlot, A.
    Pinede, D.
    Vacheron, M. N.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2011, 21 : S516 - S517
  • [39] Olanzapine in Chinese treatment-resistant patients with schizophrenia: An open-label, prospective trial
    Chiu, NY
    Yang, YK
    Chen, PS
    Chang, CC
    Lee, IH
    Lee, JR
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2003, 57 (05) : 478 - 484
  • [40] Quetiapine ('Seroquel') and olanzapine for acute treatment of patients with schizophrenia: An open-label, comparative study
    Reznik, I
    Slavkin, L
    Shabash, E
    Shaked, G
    Kertzman, S
    Spivak, B
    Weizman, A
    Kotler, M
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S244 - S244
12345